



**NC Medicaid and NC Health Choice
Pharmacy Prior Approval Request for
Immunomodulators: Plaque Psoriasis - Pediatric
(Enbrel, Stelara, and Taltz)**

Beneficiary Information

1. Beneficiary Last Name: _____ 2. First Name: _____
3. Beneficiary ID #: _____ 4. Beneficiary Date of Birth: _____ 5. Beneficiary Gender: _____

Prescriber Information

6. Prescribing Provider NPI #: _____
7. Requester Contact Information - Name: _____ Phone #: _____ Ext. _____

Drug Information

8. Drug Name: _____ 9. Strength: _____ 10. Quantity Per 30 Days: _____
11. Length of Therapy (in days): up to 30 Days 60 Days 90 Days 120 Days 180 Days 365 Days Other _____

Clinical Information

1. Is the beneficiary age 6 or older? Yes No
 2. Does the beneficiary have a diagnosis of moderate to severe Plaque Psoriasis and is a candidate for systemic therapy or phototherapy? Yes No
 3. Is the beneficiary on any other injectable immunomodulator? Yes No
 4. Has the beneficiary been screened for latent tuberculosis infection? Yes No
 5. Has the beneficiary been tested with Hep B SAG and Core Ab? Yes No
 6. Has the beneficiary experienced a therapeutic failure or inadequate response with, or has a contraindication or intolerance to methotrexate? Yes No
 7. Does the beneficiary have a body surface area (BSA) involvement of at least 3%? Yes No
 8. Does the beneficiary have involvement of the palms, soles, head and neck, or genitalia; causing disruption in normal daily activities and/or employment? Yes No
 9. Has the beneficiary tried and failed Enbrel? Yes No
- 9a. If no, please provide the clinical reason why the beneficiary has not tried Enbrel: _____

Signature of Prescriber: _____ Date: _____

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability. _____

Fax this form to CSRA at (855) 710-1969

Pharmacy PA Call Center: (866) 246-8505

DHB Pharmacy 52

2/3/2021